Auriga Files New Cutting-Edge Patent Application to Expand Revenues and Product Exclusivity in Multibillion-Dollar Markets.

Patent Strengthens Company's Intellectual Property Portfolio to Broaden Brand Portfolio in Major Prescription Drug Segments

NORCROSS, Ga. -- Auriga Laboratories, Inc. (OTCBB:ARGA), a specialty pharmaceutical company driving high-growth revenues through acquisition of valuable brand portfolios and innovative drug development programs, today announced the filing of a new provisional patent application for a key drug delivery platform technology that will provide market exclusivity for its proprietary product pipeline and proven pharmaceutical brands.

The recent filing, which includes an innovative delivery technology to administer an active ingredient in popular over-the-counter cold products, strengthens Auriga's business model to acquire and develop proprietary brands in the prescription drug marketplace, and then to maximize potential revenues through aggressive and broad intellectual property protection and innovative sales and marketing strategies.

The patent, titled "Formulations for the Prevention and Treatment of Infectious Rhinitis Utilizing Pharmacologic Agents in combination with Zinc," allows Auriga to insert zinc into the Extendryl, Levall and other product lines, giving patients the immune augmentation from the zinc along with the symptomatic relief from the cough and cold medicine. Zinc has been shown by peer-reviewed clinical studies to significantly reduce the duration of the common cold, as well as the severity of cold symptoms such as sore throat, stuffy nose, sneezing, coughing and congestion. The present invention provides an alternative method for treating both the symptoms of infectious rhinitis and eliminating the underlying pathogenic organisms without the use of antibiotics.

The proprietary technology will be used to expand such Auriga brands as the Extendryl[R] line, which currently comprises seven different prescription drug products. Additionally, the Company will leverage the new technology to extend the market exclusivity of other Auriga prescription drug products, such as its Levall[R] brand, which includes four popular trademarked product lines.

"Our innovative business model is driven by our expanding library of drug delivery technologies that allow us to reduce capital requirements, risk and product time-to-market," said Philip S. Pesin, Chief Executive Officer of Auriga. "This particular patent application is exciting because it will improve the effectiveness and yield market exclusivity for our Levall and Extendryl family of products for the multibillion-dollar common cold markets."

Auriga develops pharmaceutical products based on patented drug delivery technologies that match an understanding of patient physiology with advances in cellular biology, material science, and pharmaceutics. Its business strategy has been designed to minimize the capital requirements, risk and product time-to-market through the acquisition and reformulation of undervalued products for extended market exclusivity.

About Auriga Laboratories(TM)

Auriga Laboratories(TM) is a specialty pharmaceutical company capitalizing on high-revenue markets and opportunities in the pharmaceutical industry through proactive sales, integrated marketing and advanced in-house drug development capabilities. The Company's high-growth business model combines acquisition of proven brand names, powerful product development strategies and rapidly-growing national sales teams and marketing operations. Auriga acquires valuable brand portfolios that are no longer a strategic focus for large pharmaceutical companies, then capitalizes on untapped marketplace opportunities through brand extension and directed sales/marketing programs. The Company's drug-development pipeline leverages novel material science and advanced drug delivery technologies to produce improved formulations of successful brands to further expand markets, sales and clinical indications for proven, successful products. Auriga's exclusive product portfolio currently includes the Extendryl[R] and Levall[R] families of prescription products, indicated for relief of symptoms associated with a range of acute respiratory diseases. Auriga's product portfolio also consists of Aquoral(TM) for the treatment of Xerostomia. Auriga plans to become a fully integrated pharmaceutical company by acquiring its own manufacturing and development capabilities. Moving forward, the Company will seek to acquire and/or in-license additional products and technologies to further grow revenues. For more information, please visit: www.aurigalabs.com. For investor-specific information and resources, visit http://www.trilogy-capital.com/tcp/auriga/. For an informational video overview, visit http://www.trilogy-capital.com/tcp/auriga/video.html. To view current stock quotes and news, visit http://www.trilogy-capital.com/tcp/auriga/quote.html.

Forward-Looking Statements

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from our expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in our documents filed from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Statements regarding the regulatory status and/or regulatory compliance of our products, our ability to secure additional financing, our ability to sustain market acceptance for our products, our dependence on collaborators, our ability to find and execute strategic transactions, or potential exposure to litigation, our exposure to product liability claims, and our prices, future revenues and income and cash flows and other statements that are not historical facts contain predictions, estimates and other forward-looking statements. Although the Company believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved and these statements will prove to be accurate. Important factors could cause actual results to differ materially from those included in the forward-looking statements.